Mayo Foundation for Medical Education and Research

Bianca A Thomae

Richard M Weinshilboum

Eric D Wieben

Araba A Adjei

Yuan Ji

Thomas C Wood

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.

Sulfotransferase 1E1 sequence variants

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are sulfotransferase allozymes. Methods for determining the sulfonator status of a subject also are described. In addition, methods for predicting the therapeutic efficacy of a compound in a subject are described, as are methods for estimating the dose of a compound to be administered to a subject.

Sulfotransferase 2B1 pharmacogenetics

Isolated sulfotransferase 1A3 nucleic acid molecules and polypeptides that include nucleotide sequence variants and amino acid sequence variants are described. Methods for determining predisposition to particular clinical conditions and methods for determining sulfonator status also are described.

Sulfotransferase 1A3 sequence variants

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to a heart condition or cancer also are described.

Sulfotransferase SULT2A1 sequence variants

Isolated PNMT nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as PNMT allozymes. Methods for determining if a subject is predisposed to multiple sclerosis, early-onset Alzheimer's disease, or Parkinson's disease also are described.

Phenylethanolamine-N-methyltransferase sequence variants

Isolated ASMT nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as ASMT allozymes. Methods for determining if a mammal is at risk for toxicity from acute or chronic arsenic exposure also are described.

Growing community of inventors

Chicago, IL, United States of America

Bianca A Thomae